World’s Most Pregnant Brand Advocate Slammed by the FDA

A big #PRWin for the Food and Drug Administration?

ICYMI (regretfully, you didn’t) yesterday Kim Kardashian took to Twitter with a naked tweet showcasing her preggers body. You know, again.

While she surprised no one with her overly modest self-portrait, she did attract the attention of a new fan: the Food and Drug Association (FDA). Typically, social media responds to her inane tweets, posts, and ‘grams as if she were some sort of bathroom oracle–but the U.S. Government did not take too kindly to her latest insights.

As you can see, Kardashian, 34, was trying to prove to the masses that she deserves some sympathy for having morning sickness. And because of her plight, she decided to shill shamelessly for the drug Diclegis.

kimkardashian-drug-instagram

The problem was that Dr. K didn’t disclose the fact that this was a paid endorsement OR mention that the product may carry risks for the baby. To wit, the FDA sent her an official warning letter. Here’s the copy her team wrote:

“[My doctor] prescribed me #Diclegis, I felt a lot better and most importantly, it’s been studied and there was no increased rick to the baby. I’m so excited and happy with my results that I’m partnering with Duchesnay USA to raise awareness about treating morning sickness.”

In its letter, the FDA shares the fact that the drug hasn’t been tested to treat what is technically known as “hyperemesis gravidarum,” a pregnancy condition that leads to nausea, vomiting and dehydration.

The Washington Post reveals that this isn’t the first complaint levied against the makers of Diclegis. Duchesnay (the drug’s producer) was notified of an infraction in November 2013 when the drug was first announced. “OPDP is concerned that Duchesnay is continuing to promote Diclegis in a violative manner,” the FDA wrote.

So there’s no #PRFail involved in this paid plug. Kim gets her cash, Diclegis gets some traffic and the FDA gets to do what most of us wish we could do: tell this woman to cut it out.